Where many biotech companies have decided to maintain their massive genomic/proteomic databases in-house, Oxford GlycoSciences plc believes its drug discovery business will be more focused and cost effective by leaving the database curator job to a separate entity.

Therefore, Oxford GlycoSciences (LSE:OGS; OGSI) last week agreed to form Confirmant Ltd., a 50-50 joint venture with Marconi plc (LSE:MONI; MONI) that will concentrate on three business lines: managed IT